Haleon PLC Executes Share Buyback to Optimize Capital Structure

Haleon PLC ( (GB:HLN) ) has shared an announcement.

Haleon PLC announced the purchase of 802,236 ordinary shares as part of its share buyback program, initially announced in March 2025. This transaction, aimed at optimizing the company’s capital structure, reduces the number of shares with voting rights to 9,005,256,948, potentially impacting shareholder interests and market positioning.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Spark’s Take on GB:HLN Stock

According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.

Haleon PLC’s strong financial performance and bullish technical indicators are the primary drivers of the stock’s favorable score. The company’s strategic initiatives, including a share buyback program, further bolster its market position. However, the high P/E ratio and potential valuation concerns slightly temper the score.

To see Spark’s full report on GB:HLN stock, click here.

More about Haleon PLC

Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. The company offers products across six major categories: Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Its portfolio includes well-known brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.

Average Trading Volume: 27,931,455

Technical Sentiment Signal: Buy

Current Market Cap: £36.84B

For a thorough assessment of HLN stock, go to TipRanks’ Stock Analysis page.